बेल्जियम - अंग्रेज़ी - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bipharma b.v. - travoprost 0,04 mg/ml - eye drops, solution - 40 µg/ml - travoprost 0.04 mg/ml - travoprost

बेल्जियम - अंग्रेज़ी - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - travoprost 0,04 mg/ml - eye drops, solution - 40 µg/ml - travoprost 0.04 mg/ml - travoprost

बेल्जियम - अंग्रेज़ी - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - travoprost 0,004 % v/v - 100 % v/v - eye drops, solution - 40 µg/ml - travoprost 0.04 mg/ml - travoprost

इसराइल - अंग्रेज़ी - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - travoprost - ophthalmic solution - travoprost 0.04 mg/ml - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

physicians total care, inc. - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travoprost 0.04 mg in 1 ml - travatan z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. none pregnancy category c teratogenic effects: travoprost was teratogenic in rats, at an intravenous (iv) dose up to 10 mcg/kg/day (250 times the maximal recommended human ocular dose (mrhod), evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, such as fused sternebrae, domed head and hydrocephaly. travoprost was not teratogenic in rats at iv doses up to 3 mcg/kg/day (75 times the mrhod), or in mice at subcutaneous doses up to 1 mcg/kg/day (25 times the mrhod). travoprost produced an increase in post-implantation losses and a decrease in fetal viability in rats at iv doses > 3 mcg/kg/day (75 times the mrhod) and in mice at subcutaneous doses > 0.3 mcg/kg/day (7.5 times the mrhod). in the offspring of female rats that received travoprost subcutaneously from day 7 of preg

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

alcon laboratories, inc - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travoprost 0.04 mg in 1 ml - travatan z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. none. risk summary there are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. in animal reproduction studies, subcutaneous (sc) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. advise pregnant women of a potential risk to a fetus. because animal reproductive studies are not always predictive of human response, travatan z should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - travoprost 40 µg/ml - eye drops, solution - 40 mcg/ml - active: travoprost 40 µg/ml excipient: benzalkonium chloride boric acid disodium edetate 1 m sodium hydroxide/1 m hydrochloric acid (ph 5.8-6.2) mannitol polyethylene glycol hydrogenated castor oil purified water trometamol - dp-travoprost eye drops are indicated to decrease elevated intraocular pressure in ocular hypertension and open-angle glaucoma as monotherapy or as adjunctive therapy.

इसराइल - अंग्रेज़ी - Ministry of Health

novartis israel ltd - travoprost - ophthalmic solution - travoprost 0.004 %w/v - travoprost - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - travoprost, quantity: 40 microgram/ml - eye drops, solution - excipient ingredients: boric acid; ethoxylated hydrogenated castor oil; polyquaternium-1; sodium hydroxide; mannitol; hydrochloric acid; propylene glycol; purified water; sodium chloride - travatan eye drops are indicated to decrease elevated intraocular pressure in: - ocular hypertension. - open-angle glaucoma. travatan eye drops may be used: - as first line monotherapy. - as adjunctive therapy.

माल्टा - अंग्रेज़ी - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - travoprost - eye drops, solution - travoprost 40 µg/ml - ophthalmologicals